Back to top
more

Catalyst Biosciences, Inc. (CBIO)

(Delayed Data from NSDQ)

$8.46 USD

8.46
151,794

+0.26 (3.17%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.45 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy

A phase II study is ongoing on Merck's (MRK) MK-2060 in people with end-stage renal disease receiving hemodialysis.

Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?

Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.

Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?

Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.

Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know

Catalyst Biosciences, Inc. (CBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates

Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of 5.88% and 13.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?

Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.

Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season?

Catalyst Biosciences (CBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Catalyst Biosciences, Inc. (CBIO) Reports Q1 Loss, Tops Revenue Estimates

Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of -2.60% and 46.70%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Select Medical (SEM) Earnings in Q1?

Select Medical (SEM) Q1 results are likely to reflect improvement in patient volumes.

Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study

Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.

Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer

The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.

Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod

Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six to 11.

Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies

Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.

Zacks.com featured highlights include: ODP, Myers, Catalyst, Vicor and Bally's

Zacks.com featured highlights include: ODP, Myers, Catalyst, Vicor and Bally's

Shrabana Mukherjee headshot

5 Stocks to Keep an Eye on as Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might led to solid price appreciation for stocks like ODP (ODP), Myers (MYE), Catalyst Biosciences (CBIO), Vicor (VICR) and Bally's (BALY).

Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

Shrabana Mukherjee headshot

5 Stocks Set to Pop on New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Biosciences (CSTL).

Top Ranked Momentum Stocks to Buy for April 21st

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 21st

Catalyst Biosciences Enters Oversold Territory

Catalyst Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Company News For Dec 20, 2019

Companies In The News Are: CAG, CBIO, MLHR, DRI

Company News For Oct 4, 2019

Companies in the news are: STZ, BBBY, PEP, CBIO

Catalyst Biosciences Enters Oversold Territory

Catalyst Biosciences, Inc. (CBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll

Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll